Company Overview
VolitionRx Limited operates as a multinational epigenetics company focused on developing blood tests designed to detect and monitor various cancers, as well as diseases associated with NETosis, across the United States, Europe, and Asia. Within the broader healthcare sector, the company specifically functions within the medical devices industry, where its primary product offering includes Nu.Q Vet, a cancer screening test for dogs and other animals, alongside Nu.Q Nets for disease detection. The organization maintains a relatively small operational footprint with an employee count of 75, reflecting a lean organizational structure typical of early-stage biotechnology firms. The company's current market capitalization stands at $26.65M, while its trailing twelve-month revenue is recorded at $1.47M, figures that collectively indicate a small-cap status with limited revenue generation relative to its valuation metrics. This valuation structure suggests the market is pricing the company based on potential future clinical developments or partnerships rather than current operational profitability, as the revenue base remains modest in absolute terms.
Financial Health
VolitionRx Limited reported trailing twelve-month revenue of $1.47M against a net income of $-22,879,568 and an EBITDA of $-21,653,004, revealing a significant disparity where operating expenses substantially exceed revenue generation. The company recorded free cash flow of $-30,988,876, which indicates a heavy burn rate and limited financial flexibility, suggesting that external capital sources are necessary to fund ongoing research and development activities. Analysis of the company's margins shows a gross margin of 100.0%, an operating margin of -813.2%, and a profit margin of 0.0%, illustrating that while the cost of goods sold is negligible relative to sales, high overhead costs are driving the operating loss well beyond the revenue figure. In terms of balance sheet leverage, the company holds $199,407 in cash while carrying $11.26M in debt, resulting in a negative price-to-book ratio of -0.62 and a forward P/E of -2.18, which points to a highly leveraged position where liabilities significantly outweigh liquid assets. The current ratio is listed at 0.12, a figure that critically indicates the company possesses far fewer current assets than current liabilities, signaling severe short-term liquidity constraints. Furthermore, the return on equity is marked as N/A due to the capital structure, while the return on assets stands at -148.3%, demonstrating that management is currently generating negative returns on the assets employed by the business.
Valuation Assessment
The trailing P/E ratio is listed as N/A due to the lack of positive net income, whereas the forward P/E is -2.18, a divergence that implies the market is attempting to value future earnings potential despite current losses. The price-to-book ratio is -0.62, which indicates that the market is valuing the company at a discount to its theoretical book value, a common occurrence for firms with significant accumulated deficits or negative equity positions. Alternative valuation metrics such as the price-to-sales ratio of 18.11 and an EV/EBITDA of -1.56 suggest that investors are placing a premium on the company's revenue growth potential and intellectual property rather than current cash flow or earnings. The stock has traded between a 52-week low of $0.17 and a 52-week high of $0.94, meaning the current price sits at a point where the stock has experienced substantial volatility within this specific trading range. The beta value of 1.36 indicates that the stock's price volatility is 36% higher than the broader market, suggesting that share price movements will likely be more pronounced during periods of market stress or rally compared to large-cap counterparts. These metrics collectively portray a high-risk, high-volatility instrument where valuation is driven by speculative expectations rather than fundamental cash flow generation.
Growth & Income
VolitionRx Limited reported a revenue growth rate of 32.2% year-over-year, while the earnings growth rate is N/A due to the company's consistent losses, implying that top-line expansion is occurring without a corresponding improvement in profitability. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings are theoretically available for reinvestment but are currently consumed by operational losses rather than distributed to shareholders. The absence of a dividend policy suggests the company reinvests its limited resources and any potential future earnings back into research, development, and clinical trials to advance its epigenetics testing platforms. Overall, the growth and income profile is characterized by strong revenue expansion coupled with significant cash burn and a complete lack of income distribution to investors.